Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter - PubMed (original) (raw)
. 2003 Feb 1;63(3):636-41.
Annemieke de Jong, Susan J F van den Eeden, Jeanette M van der Hulst, Kitty M C Kwappenberg, Sabrin Hassane, Kees L M C Franken, Jan Wouter Drijfhout, Gert Jan Fleuren, Gemma Kenter, Cornelis J M Melief, Rienk Offringa, Sjoerd H van der Burg
Affiliations
- PMID: 12566307
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter
Marij J P Welters et al. Cancer Res. 2003.
Abstract
Genital human papillomavirus (HPV) infection is common and the majority of infected individuals successfully deal with this virus. Clearance of HPV is presumably mediated by T cells but HPV-16-specific T-cell memory was usually detected in patients with progressive disease and not in healthy subjects, suggesting that HPV-immunity comes too late. We now show the presence of HPV-16 E6-specific memory T-helper (Th) responses in a major fraction (12 of 20) of healthy individuals by application of the IFN-gamma-ELISPOT assay. Although nearly all E6-peptides were recognized, the majority of the responders targeted peptide sequences of the COOH-terminal half (E6(81-158)) of HPV-16 E6. In a direct comparison, the presence of HPV-16 E6-specific T cells coincided with HPV-16 E2-specific T-cell reactivity in healthy individuals, whereas hardly any HPV-16 E7-specific Th immunity was found. This indicates that the induction of T-cell reactivity against HPV-16 E7 is suboptimal during infection when compared with that against HPV-16 E2 and HPV-16 E6. In conclusion, the presence of HPV-16 E6-specific Th memory in the healthy population demonstrates that HPV infection leads to T-cell immunity against immediate early proteins expressed during infection. Because this HPV-16 E6-specific T-cell immunity was frequently detected in healthy subjects, our data suggest that the observed IFN-gamma-producing proliferating T cells circulating in the peripheral blood play a role in protection against persistent HPV infection and associated development of malignancies.
Similar articles
- Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R. de Jong A, et al. Cancer Res. 2002 Jan 15;62(2):472-9. Cancer Res. 2002. PMID: 11809698 - Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH. Welters MJ, et al. Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880. Clin Cancer Res. 2008. PMID: 18172269 Clinical Trial. - HPV: from infection to cancer.
Stanley MA, Pett MR, Coleman N. Stanley MA, et al. Biochem Soc Trans. 2007 Dec;35(Pt 6):1456-60. doi: 10.1042/BST0351456. Biochem Soc Trans. 2007. PMID: 18031245 Review. - Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia.
Sheu BC, Chang WC, Lin HH, Chow SN, Huang SC. Sheu BC, et al. J Obstet Gynaecol Res. 2007 Apr;33(2):103-13. doi: 10.1111/j.1447-0756.2007.00492.x. J Obstet Gynaecol Res. 2007. PMID: 17441881 Review.
Cited by
- The immune microenvironment of cancer of the uterine cervix.
Mastrogeorgiou M, Chatzikalil E, Theocharis S, Papoudou-Bai A, Péoc'h M, Mobarki M, Karpathiou G. Mastrogeorgiou M, et al. Histol Histopathol. 2024 Oct;39(10):1245-1271. doi: 10.14670/HH-18-727. Epub 2024 Mar 1. Histol Histopathol. 2024. PMID: 38483012 Review. - Peripheral Blood T-lymphocyte Phenotypes in Mother-Child Pairs Stratified by the Maternal HPV Status: Persistent HPV16 vs. HPV-Negative: A Case-Control Study.
Suominen H, Paaso A, Koskimaa HM, Grénman S, Syrjänen K, Syrjänen S, Louvanto K. Suominen H, et al. Viruses. 2022 Nov 25;14(12):2633. doi: 10.3390/v14122633. Viruses. 2022. PMID: 36560637 Free PMC article. - Effects of hypoxia on antigen presentation and T cell-based immune recognition of HPV16-transformed cells.
Mohan N, Wellach K, Özerdem C, Veits N, Förster JD, Foehr S, Bonsack M, Riemer AB. Mohan N, et al. Front Immunol. 2022 Oct 21;13:918528. doi: 10.3389/fimmu.2022.918528. eCollection 2022. Front Immunol. 2022. PMID: 36341354 Free PMC article. - Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F. Speetjens FM, et al. J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016. J Immunother Cancer. 2022. PMID: 36261215 Free PMC article. Clinical Trial. - The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies.
Zheng K, Egawa N, Shiraz A, Katakuse M, Okamura M, Griffin HM, Doorbar J. Zheng K, et al. Viruses. 2022 Jan 22;14(2):214. doi: 10.3390/v14020214. Viruses. 2022. PMID: 35215808 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases